GeneBioTech Ltd (A086060) Stock Overview
Engages in the manufacture and sale of feed additives and functional food in South Korea. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 5/6 |
| Dividends | 2/6 |
A086060 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
GeneBioTech Co. ,Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩4,665.00 |
| 52 Week High | ₩5,990.00 |
| 52 Week Low | ₩3,400.00 |
| Beta | 0.53 |
| 1 Month Change | -2.61% |
| 3 Month Change | 5.07% |
| 1 Year Change | 35.02% |
| 3 Year Change | 8.49% |
| 5 Year Change | -29.96% |
| Change since IPO | -45.18% |
Recent News & Updates
Investors Continue Waiting On Sidelines For GeneBioTech Co. ,Ltd (KOSDAQ:086060)
Nov 14
Here's Why GeneBioTech Ltd (KOSDAQ:086060) Has Caught The Eye Of Investors
Aug 11Recent updates
Investors Continue Waiting On Sidelines For GeneBioTech Co. ,Ltd (KOSDAQ:086060)
Nov 14Here's Why GeneBioTech Ltd (KOSDAQ:086060) Has Caught The Eye Of Investors
Aug 11Is GeneBioTech Ltd (KOSDAQ:086060) A Risky Investment?
May 15GeneBioTech Ltd's (KOSDAQ:086060) Soft Earnings Are Actually Better Than They Appear
Nov 21Market Cool On GeneBioTech Co. ,Ltd's (KOSDAQ:086060) Earnings
Aug 12We Like The Quality Of GeneBioTech Ltd's (KOSDAQ:086060) Earnings
Mar 22Read This Before Buying GeneBioTech Co. ,Ltd (KOSDAQ:086060) For Its Dividend
Apr 15Should GeneBioTech Ltd (KOSDAQ:086060) Be Disappointed With Their 90% Profit?
Mar 18Here's Why Genebiotech (KOSDAQ:086060) Has A Meaningful Debt Burden
Feb 17
How Does Genebiotech Co., Ltd. (KOSDAQ:086060) Fare As A Dividend Stock?
Jan 10Is Genebiotech (KOSDAQ:086060) A Risky Investment?
Nov 19Shareholder Returns
| A086060 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | -3.7% | -4.1% | 1.6% |
| 1Y | 35.0% | 35.4% | 147.0% |
Return vs Industry: A086060 matched the KR Biotechs industry which returned 35.4% over the past year.
Return vs Market: A086060 underperformed the KR Market which returned 147% over the past year.
Price Volatility
| A086060 volatility | |
|---|---|
| A086060 Average Weekly Movement | 5.1% |
| Biotechs Industry Average Movement | 11.0% |
| Market Average Movement | 9.1% |
| 10% most volatile stocks in KR Market | 16.1% |
| 10% least volatile stocks in KR Market | 4.7% |
Stable Share Price: A086060 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A086060's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 41 | Chan-Ho Lee | www.genebiotech.co.kr |
GeneBioTech Co. ,Ltd, together with its subsidiaries, engages in the manufacture and sale of feed additives and functional food in South Korea. It also manufactures and sells animal drugs. The company was founded in 2000 and is headquartered in Gongju-si, South Korea.
GeneBioTech Co. ,Ltd Fundamentals Summary
| A086060 fundamental statistics | |
|---|---|
| Market cap | ₩40.17b |
| Earnings (TTM) | ₩3.79b |
| Revenue (TTM) | ₩90.79b |
Is A086060 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A086060 income statement (TTM) | |
|---|---|
| Revenue | ₩90.79b |
| Cost of Revenue | ₩76.53b |
| Gross Profit | ₩14.26b |
| Other Expenses | ₩10.47b |
| Earnings | ₩3.79b |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 440.02 |
| Gross Margin | 15.70% |
| Net Profit Margin | 4.17% |
| Debt/Equity Ratio | 26.9% |
How did A086060 perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/02 04:17 |
| End of Day Share Price | 2026/04/30 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
GeneBioTech Co. ,Ltd is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.